CO2022015048A2 - Métodos y composiciones para tratar o prevenir una afección inflamatoria - Google Patents
Métodos y composiciones para tratar o prevenir una afección inflamatoriaInfo
- Publication number
- CO2022015048A2 CO2022015048A2 CONC2022/0015048A CO2022015048A CO2022015048A2 CO 2022015048 A2 CO2022015048 A2 CO 2022015048A2 CO 2022015048 A CO2022015048 A CO 2022015048A CO 2022015048 A2 CO2022015048 A2 CO 2022015048A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- compositions
- inflammatory condition
- inflammatory
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901030A AU2020901030A0 (en) | 2020-04-02 | A method of treatment | |
| AU2020902432A AU2020902432A0 (en) | 2020-07-14 | A method of treatment | |
| AU2020903985A AU2020903985A0 (en) | 2020-11-02 | A method of treatment | |
| AU2020904264A AU2020904264A0 (en) | 2020-11-18 | A method of treatment | |
| AU2021900241A AU2021900241A0 (en) | 2021-02-03 | A method of treatment | |
| AU2021900324A AU2021900324A0 (en) | 2021-02-10 | A method of treatment | |
| PCT/AU2021/050226 WO2021195691A1 (en) | 2020-04-02 | 2021-03-15 | Methods and compositions for treating or preventing an inflammatory condition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022015048A2 true CO2022015048A2 (es) | 2022-11-08 |
Family
ID=77926837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0015048A CO2022015048A2 (es) | 2020-04-02 | 2022-10-21 | Métodos y composiciones para tratar o prevenir una afección inflamatoria |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230128114A1 (https=) |
| EP (1) | EP4125835A4 (https=) |
| JP (1) | JP2023521634A (https=) |
| AU (1) | AU2021250462A1 (https=) |
| CA (1) | CA3169702A1 (https=) |
| CO (1) | CO2022015048A2 (https=) |
| IL (1) | IL296943A (https=) |
| WO (1) | WO2021195691A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240325312A1 (en) * | 2021-07-15 | 2024-10-03 | Incannex Healthcare Limited | Composition comprising cannabidiol and hydroxychloroquine in a fixed dose combination capsule |
| WO2024025525A1 (en) * | 2022-07-27 | 2024-02-01 | Medterra Pharma Llc | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453431A (en) * | 1993-10-29 | 1995-09-26 | Gilman; Andrew L. | Use of hydroxychloroquine for treatment of graft-versus-host disease |
| GB9807639D0 (en) * | 1998-04-14 | 1998-06-10 | Kennedy Rheumatology Inst | Anti-inflammatory agents |
| US20040242632A1 (en) * | 2001-11-09 | 2004-12-02 | Charous B. Lauren | Method for treating inflammatory bowel disease |
| US20200009077A1 (en) * | 2018-07-03 | 2020-01-09 | TRUETIVA, Inc. | Compositions for treating dermatological diseases |
| CN115916336A (zh) * | 2020-02-19 | 2023-04-04 | 施里玛·麦钱特 | 大麻二酚的组合物和治疗用途 |
-
2021
- 2021-03-15 US US17/907,322 patent/US20230128114A1/en active Pending
- 2021-03-15 AU AU2021250462A patent/AU2021250462A1/en active Pending
- 2021-03-15 IL IL296943A patent/IL296943A/en unknown
- 2021-03-15 JP JP2022559967A patent/JP2023521634A/ja active Pending
- 2021-03-15 EP EP21781628.9A patent/EP4125835A4/en active Pending
- 2021-03-15 WO PCT/AU2021/050226 patent/WO2021195691A1/en not_active Ceased
- 2021-03-15 CA CA3169702A patent/CA3169702A1/en active Pending
-
2022
- 2022-10-21 CO CONC2022/0015048A patent/CO2022015048A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021250462A1 (en) | 2022-12-01 |
| WO2021195691A1 (en) | 2021-10-07 |
| IL296943A (en) | 2022-12-01 |
| EP4125835A4 (en) | 2024-05-22 |
| JP2023521634A (ja) | 2023-05-25 |
| EP4125835A1 (en) | 2023-02-08 |
| US20230128114A1 (en) | 2023-04-27 |
| CA3169702A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022015048A2 (es) | Métodos y composiciones para tratar o prevenir una afección inflamatoria | |
| Bilen et al. | The Queen's Gambit: Explaining the superstar effect using evidence from chess | |
| CO2019008986A2 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
| CO2020010342A2 (es) | Composiciones de arni de 17 β -hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas | |
| MX2022001337A (es) | Uso de cannabidiol en el tratamiento del sindrome de dravet. | |
| CL2009000198A1 (es) | Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica. | |
| CL2019001334A1 (es) | Pirrolopirimidinas como potenciadores de cftr. | |
| CL2012001298A1 (es) | Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras. | |
| CY1115708T1 (el) | Τοπικες συνθεσεις για τη διατηρηση ή την ανακτηση της ακεραιοτητας των βλεννογονων | |
| CL2011002787A1 (es) | Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica. | |
| CL2011000301A1 (es) | Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer. | |
| MX2018005166A (es) | Mezcla de tabaco. | |
| BR112015006571A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados | |
| UY30794A1 (es) | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinic0 | |
| ECSP10010216A (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso | |
| CL2011000696A1 (es) | Particulas inhalables que comprenden una forma anhidra amorfa de tiotropio con un agente estabilizante que es lactosa; composicion farmaceutica; procedimiento para prepararlas que incluye secado por atomizacion; y su uso en asma y epoc | |
| BR112015012871A2 (pt) | secador para secar uma placa, e, sistema de secagem | |
| MX2019006881A (es) | Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas. | |
| NO341676B1 (no) | Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI | |
| BR112012008276A2 (pt) | instrumento para inspeção visual ou manutenção de turbinas | |
| CL2013002542A1 (es) | Uso de una composicion farmaceutica inhalable que contiene glicopirrolato o una sal del mismo para el tratamiento o profilaxis de taquicardia en pacientes con enfermedad pulmonar obstructiva cronica, asma, fibrosis quistica y enfermedades relacionadas de las vias aereas. | |
| CL2010001459A1 (es) | Compuesto derivados de benzoxazinona; compuesto intermediarios; composicion y combinacion farmaceutica; y uso para el trratamiento de enfermedades tales como insuficiencia respiratoria en el adulto, enfisema pulmonar, bronquitis, epoc, entre otras. | |
| BR112014007127A2 (pt) | métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit | |
| MX2023010126A (es) | Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miebro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda. | |
| BR112014007463A2 (pt) | método e aparelho de pré-tratamento por moagem de farinha para fabricação de farinha de arroz |